1. Home
  2. NUAI vs CABA Comparison

NUAI vs CABA Comparison

Compare NUAI & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Era Energy & Digital Inc.

NUAI

New Era Energy & Digital Inc.

HOLD

Current Price

$4.61

Market Cap

190.3M

Sector

Energy

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.85

Market Cap

212.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUAI
CABA
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
212.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NUAI
CABA
Price
$4.61
$2.85
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$14.57
AVG Volume (30 Days)
7.5M
4.3M
Earning Date
03-31-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$843,029.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
50.89
N/A
52 Week Low
$0.32
$0.99
52 Week High
$9.45
$3.67

Technical Indicators

Market Signals
Indicator
NUAI
CABA
Relative Strength Index (RSI) 43.15 58.18
Support Level $4.78 $2.29
Resistance Level $5.39 $2.69
Average True Range (ATR) 1.00 0.21
MACD -0.30 -0.00
Stochastic Oscillator 0.26 55.49

Price Performance

Historical Comparison
NUAI
CABA

About NUAI New Era Energy & Digital Inc.

New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: